Publication Name	World Journal of Gastroenterology
Manuscript ID	26605
Country	Lebanon

Received	2016-04-19 09:57
Peer-Review Started	2016-04-19 17:03
To Make the First Decision	2016-05-27 14:57
Return for Revision	2016-05-28 14:01
Revised	2016-06-17 00:00
Second Decision	2016-06-28 09:06
Accepted by Journal Editor-in-Chief	2016-06-29 01:21
Accepted by Company Editor-in-Chief	2016-07-06 18:30
Articles in Press	2016-07-06 18:30
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2016-07-21 10:25
Publish the Manuscript Online	2016-07-29 20:32

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Review
Article Title	Use of rifaximin in gastrointestinal and liver diseases
Manuscript Source	Invited Manuscript
All Author List	Rani H Shayto, Rachel Abou Mrad and Ala I Sharara
Funding Agency and Grant Number
Corresponding Author	Ala I Sharara, MD, FACG, AGAF, Professor, Head, Division of Gastroenterology, Department of Internal Medicine, American University of Beirut Medical Center, Cairo Street, Beirut 11-0236, Lebanon. ala.sharara@aub.edu.lb
Key Words	Irritable bowel syndrome; Inflammatory bowel disease; Hepatic encephalopathy; Bacterial overgrowth; Diverticular disease
Core Tip	Rifaximin is a poorly absorbed oral antibiotic with highly favorable safety profile. Rifaximin is effective in the treatment of traveler’s diarrhea, functional bloating and irritable bowel syndrome, small bowel bacterial overgrowth and in the prevention of recurrent overt hepatic encephalopathy. There is emerging evidence for a possible beneficial effect of rifaximin in the treatment of other disorders including uncomplicated diverticular disease and in the prevention of recurrent diverticulitis. The use of rifaximin is associated with a low incidence of development of spontaneous bacterial mutants or drug resistance among extra-intestinal flora.
Publish Date	2016-07-29 20:32
Citation	Shayto RH, Abou Mrad R, Sharara AI. Use of rifaximin in gastrointestinal and liver diseases. World J Gastroenterol 2016; 22(29): 6638-6651
URL	http://www.wjgnet.com/1007-9327/full/v22/i29/6638.htm
DOI	http://dx.doi.org/10.3748/wjg.v22.i29.6638

Full Article (PDF)	WJG-22-6638.pdf
Full Article (Word)	WJG-22-6638.doc
Manuscript File	26605-Review.docx
Answering Reviewers	26605-Answering reviewers.pdf
Audio Core Tip	26605-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	26605-Conflict-of-interest statement.pdf
Copyright License Agreement	26605-Copyright assignment.pdf
Peer-review Report	26605-Peer-review(s).pdf
Journal Editor-in-Chief Review Report	26605-Journal editor-in-chief review report.pdf
Scientific Misconduct Check	26605-Scientific misconduct check.pdf
Scientific Editor Work List	26605-Scientific editor work list.pdf